San Diego, CA -- (SBWire) -- 06/05/2017 --An investor, who purchased shares of Neurotrope Inc (NASDAQ:NTRP), filed a lawsuit against Neurotrope Inc over alleged Securities Laws violations.
Investors who purchased shares of Neurotrope Inc (NASDAQ:NTRP) have certain options and for certain investors are short and strict deadlines running. Deadline: July 17, 2017. NASDAQ:NTRP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
According to the complaint the plaintiff alleges on behalf of purchasers of Neurotrope Inc (NASDAQ:NTRP) common shares between January 7, 2016, and April 28, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 7, 2016, and April 28, 2017 Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1.
On May 1, 2017, Neurotrope Inc announced "positive top-line results" of the pivotal Phase 2b trials of Bryostatin-1, noting "improvement in patients with moderate to severe Alzheimer's disease." However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope Inc failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Shares of Neurotrope Inc (NASDAQ:NTRP) declined to $6.42 per share on May 15, 2017.
On June 2, 2017, Neurotrope Inc (NASDAQ:NTRP) shares closed at $6.03 per share.
Those who purchased shares of Neurotrope Inc have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Shareholder Notice: Lawsuit Filed Against Neurotrope Inc (NASDAQ:NTRP)
A lawsuit was filed on behalf of investors in Neurotrope Inc (NASDAQ:NTRP) shares over alleged securities laws violations.